Watch an astonishing transformation as this rare Blue Bird Rocket Car lighter undergoes a complete restoration! Layers of rust, tarnish, and scratches are carefully removed, revealing its original ...

A pair of privately-held developers of editing-based therapies have some successes to show for their recent efforts to ...

Carlyle Group's acquisition of bluebird bio for $3 per share offers a potential but unlikely $600 million sales milestone by ...

The legendary Twitter blue bird logo, once displayed outside the company’s San Francisco headquarters, is making its way to ...

Spring skiing can be a great way to save money, experience the best snow and find an excuse to wear those bright-pink leg ...

Congress did not reauthorize the rare pediatric disease priority review program at the end of 2024. Advocates say the ripple ...

The deal ends 2Seventy’s short run as an independent company, during which it restructured, sold off research and lost nearly ...

Facing declining valuations and funding challenges, public biotechs like bluebird bio are going private to restructure, ...

In the 1920s and 1930s national heroes were the breed who sought glory by pushing the boundaries on land, water, and in the ...

Bluebird bio could be just a few months away from approval of its gene therapy for rare disease cerebral adrenoleukodystrophy (CALD) in the EU, after the EMA started an accelerated review.

As other gene editing programs fold or get sold, Arbor Biotechnologies has secured $73.9 million to advance its lead ...